To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.

119-hr9661 — To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.. Sponsored by Rep. Langworthy, Nicholas A. [R-NY-23]. Introduced 2026-07-14. House bill. 119th Congress. Latest action: Referred to the House Committee on Energy and Commerce.

119-hr9661 119th Congress House

Bill Activity

House
Introduced
2026-07-14
Introduced in House
Referred to Committee
Referred to the House Committee on Energy and Commerce.
Committee
2026-07-14
Referred to the House Committee on Energy and Commerce.
Sponsor
Rep. Langworthy, Nicholas A. [R-NY-23] (R), NY
Introduced
2026-07-14
Committees
Energy and Commerce Committee
Latest Action
Referred to the House Committee on Energy and Commerce.

No roll-call vote data available for this bill.

Explore This Bill

Investigate this bill → AI summary, roll-call breakdown, and full bill analysis